Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|November 1, 2017

BioPharm International

  • BioPharm International-11-01-2017
  • Volume 30
  • Issue 11

Dip-Molded Plastisol Y Connectors

Qosina's Y connectors are manufactured from plastisol and produced through a dip-molding process.

Qosina has added a variety of Y connectors manufactured from plastisol, also known as liquid polyvinyl chloride (PVC), a material used to make flexible components. According to the company, plastisol is Class VI approved and BPA and latex free. These connectors are produced through a dip-molding process rather than traditional injection molding.

The company offers standard and universal plastisol Y connectors. The universal style can be cut to accommodate 3/32, 1/8, 3/16, and 1/4 in. OD tubes. There are 15 different Y connector configurations, sample assortment kits, and custom design services available to meet requirements for a range of projects. 

Qosina


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.